Lista de obras - Sabrina Arena - Dominio Público Uruguay

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

scientific article published on 12 December 2019

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

artículo científico publicado en 2016

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

artículo científico publicado en 2012

Adaptive mutability of colorectal cancers in response to targeted therapies

scientific article published on 07 November 2019

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

artículo científico publicado en 2010

BRAF V600E is a determinant of sensitivity to proteasome inhibitors

artículo científico publicado en 2013

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

artículo científico publicado en 2014

Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer

artículo científico publicado en 2018

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance

artículo científico publicado en 2017

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

artículo científico publicado en 2010

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

scientific article published on 19 May 2020

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

artículo científico publicado en 2015

Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

scholarly article published in Targeted oncology

Exposure to the Tobacco Smoke Constituent 4-Aminobiphenyl Induces Chromosomal Instability in Human Cancer Cells

scientific article published on 01 August 2007

Expression and functional regulation of myoglobin in epithelial cancers

artículo científico publicado en 2009

Genetic targeting of the kinase activity of the Met receptor in cancer cells

artículo científico publicado en 2007

High-dose vitamin C enhances cancer immunotherapy

artículo científico publicado en 2020

Identification of cancer genes by mutational profiling of tumor genomes

artículo científico publicado en 2005

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

artículo científico publicado en 2010

Isogenic mutant human cells: a new tool for personalized cancer medicine

artículo científico publicado en 2010

Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers

artículo científico publicado en 2007

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

artículo científico publicado en 2016

Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.

artículo científico publicado en 2013

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

artículo científico publicado en 2016

Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells

artículo científico publicado en 2011

PIK3CA cancer mutations display gender and tissue specificity patterns

artículo científico publicado en 2008

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

artículo científico publicado en 2019

Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges

artículo científico publicado en 2021

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

artículo científico publicado en 2018

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

artículo científico publicado en 2008

TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

scientific article published on 01 October 2020

Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels

artículo científico publicado en 2013

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

artículo científico publicado en 2016

The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase.

artículo científico publicado en 2014

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.

artículo científico publicado en 2015

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

artículo científico publicado en 2013

Understanding how kinase-targeted therapies work

artículo científico publicado en 2008

Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer

artículo científico publicado en 2020

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

artículo científico publicado en 2008

p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells

artículo científico publicado en 2004

Lista de obras de Sabrina Arena

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

Adaptive mutability of colorectal cancers in response to targeted therapies

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

BRAF V600E is a determinant of sensitivity to proteasome inhibitors

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

Exposure to the Tobacco Smoke Constituent 4-Aminobiphenyl Induces Chromosomal Instability in Human Cancer Cells

Expression and functional regulation of myoglobin in epithelial cancers

Genetic targeting of the kinase activity of the Met receptor in cancer cells

High-dose vitamin C enhances cancer immunotherapy

Identification of cancer genes by mutational profiling of tumor genomes

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

Isogenic mutant human cells: a new tool for personalized cancer medicine

Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells

PIK3CA cancer mutations display gender and tissue specificity patterns

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase.

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

Understanding how kinase-targeted therapies work

Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells